Click on a filter below to refine your search. Remove a filter to broaden your search.
Those receiving pulmonologist-directed treatment have less subsequent healthcare utilization for respiratory illness.
An increase was seen in prebronchodilator forced expiratory volume in one second with dupilumab versus placebo at weeks 12 and 52.
No reduction was seen in the number of self-reported exacerbations treated with oral corticosteroids, antibiotics or both.
The GLI-Global differentiated all-cause mortality risk between normal spirometry and first grade of COPD in adjusted analyses.